Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3250)	3/30/2001 7:26:00 PM
From: Biotech Jim	Respond to of 52153

I'll take a stab at answering that. The MC4 receptor is expressed in both the spinal cord and the hypothalamus, and the neurons containing the alphaMSH peptide, the so-called hypothalamic POMC neurons, send nerve terminals to both regions. Agonist activation of the MC4 receptor, at each of these loci, results in deprivation of food intake and energy expenditure, and in control of blood flow to the urogenital area. MRK patents on MC4 agonists focus on the ED aspect, perhaps to get around the MLNM use patent for the MC4 receptor and antiobesity agents. This is my educated guess. BJ

To: Biomaven who wrote (3250)	3/30/2001 7:28:14 PM
From: scaram(o)uche	Respond to of 52153

>> Should there be a smiley after the title? << Chuckle. No, they're both brain thingies. Except when they're not, as in the case of PDE5 inhibitors (sildenafil et al.). And then I understand them. I could have clustered all of the brain thingies, I guess, but I could only remember two. Is that clear?

To: Biomaven who wrote (3250)	3/30/2001 7:33:48 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 52153

Peter...... it's perfectly clear........the MC4 receptor is expressed in both the spinal cord and the brain thingie, and the neurons containing the alphaMSH peptide, the so-called hypothalamic POMC neurons, send nerve thingies to both regions. Agonist activation of the MC4 receptor, at each of these loci, results in deprivation of food intake and energy expenditure, and in control of blood flow to the really good stuff. MRK patents on MC4 agonists focus on the ED aspect, perhaps to get around the MLNM use patent for the MC4 receptor and antiobesity agents. This is my educated thesis.